Login to Your Account

Rigel, Serono Enter $160M Aurora Kinase Inhibitor Deal

By Karen Pihl-Carey

Wednesday, October 26, 2005
A preclinical program focused on Aurora kinase inhibitors brought Rigel Pharmaceuticals Inc. its fifth oncology deal, this one signed with Serono SA and worth up to $160 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription